The FDA Expedited IND pilot is a program, opened on September 15, 2026, that pairs drug sponsors with Qualified Research Institutions to get first-in-human trials started in the United States faster, and applications close on October 30, 2026. FDA will review a Phase 1 IND's components on a rolling basis before submission instead of waiting for the whole package, and expects to pick 8 to 10 sponsor and institution pairs by December 18. For a research site, the pilot matters in one of two ways. Either your institution applies as a Qualified Research Institution, which means advisory depth across chemistry, manufacturing, nonclinical and clinical work plus the ability to activate a Phase 1 trial, or your site is the documented partner that does the activation. In both cases the part the pilot cannot speed up is the part that happens at the site: contracts, budget, IRB, staff documents and the first participant. This post covers what FDA published, who qualifies, and what a site does in the six weeks before the deadline.
In short
- Launched September 15, 2026; applications close October 30, 2026; selections by December 18.
- FDA expects 8 to 10 sponsor and institution pairs in the first cohort.
- FDA's announcement says first-in-human trials may take up to two years in the United States, and are completed much faster in China and Australia.
- An NBER paper cited by BioPharma Dive counts China-run studies rising from just under 1,000 a year in 2010 to more than 5,000 in 2024, against about 3,500 a year in the United States.
Why FDA built the Expedited IND pilot
The pilot is part of Operation TrialBlazer, the Department of Health and Human Services' effort to speed up clinical research in the United States. FDA's announcement puts the problem as time: a first-in-human trial may take up to two years to complete in the United States, while comparable trials finish much faster in China and Australia. BioPharma Dive, reporting the launch, cites a National Bureau of Economic Research paper finding that China-run studies went from just under 1,000 a year in 2010 to more than 5,000 in 2024, while the United States held at about 3,500 a year.
FDA's answer is to change the pre-IND stage rather than the review. Under the pilot, a sponsor works with a Qualified Research Institution, or QRI, that advises on the chemistry, manufacturing and controls, nonclinical and clinical parts of the application, and FDA reviews and accepts those components as each is ready. The stated aim is better first submissions and fewer clinical holds. FDA is explicit that participation "does not modify" its standards for IND review or trial conduct, and that it keeps full authority over whether a study may proceed.
Who qualifies, on each side
FDA's pilot page sets out criteria for both partners.
| Criterion | Sponsor | Qualified Research Institution |
|---|---|---|
| Location | First-in-human Phase 1 trial run in the United States | Organized in the United States, principal place of business there |
| Product or role | Novel product under CDER's Office of New Drugs, CBER's Office of Therapeutic Products or the Oncology Center of Excellence | Advice across nonclinical, CMC and clinical disciplines |
| Stage | Commercial IND, no existing clinical experience, enough nonclinical data | Able to support Phase 1 activation through its own infrastructure or documented partnerships |
| Expertise | Not specified beyond the IND | Nonclinical lead, CMC, clinical oversight by an MD or DO, clinical pharmacology, regulatory affairs, trial support |
| Governance | Not specified | Written conflict of interest procedures; IRB members kept out of pilot advisory roles if the QRI runs an IRB |
FDA says it will judge applications as a whole, weighing complexity, stage, public health need, the sponsor's profile and a spread across therapeutic areas, modalities, sponsor sizes and QRI types. No single factor decides.
What the pilot does not speed up
Cooley's July 2026 summary of TrialBlazer notes that the FDA proposal treats IRB review and clinical trial site activation as activities that run in parallel with the IND work. That is the site's half. An FDA acceptance on day one does nothing for a study that is still in budget negotiation on day sixty, and the pilot page's own QRI criterion, the ability to support Phase 1 activation through infrastructure or documented partnerships, puts that capacity inside the application.
What a research site does before October 30
- Decide which side you are on. An institution with regulatory affairs, CMC and clinical pharmacology staff in house may apply as a QRI. A site without them is a candidate for the "documented partnership" the criteria mention. Know which conversation you are having before a sponsor calls.
- Write the partnership down. If you activate trials for a QRI, the criteria want it documented. A signed agreement with named contacts is stronger than a history of working together.
- Bring the site profile up to date. Staffing, investigator experience, pharmacy, lab, overnight capacity, enrollment history. A sponsor choosing a partner in October needs it the same week, not after a feasibility questionnaire cycle.
- Map activation as a dated list. Contract, budget, IRB submission, 1572 and delegation log, training, site initiation visit, first screen. Each with an owner and a target date, so the parallel work FDA assumes is actually parallel.
- Clear the binder of expiring documents. CVs, licences, GCP training and financial disclosures are the items that stall activation at the last step. The regulatory binder guide lists them by expiry.
- Check the IRB separation if you run one. FDA requires written procedures that keep IRB members out of the QRI's pilot advisory work.
The mistake most sites make at step 4
They treat startup as a sequence and wait for each step to finish before starting the next. The pilot's whole premise is compression, and a first-in-human study that reaches the site after an accelerated FDA review will sit in the same queue as every other study if the budget waits for the contract and the IRB waits for the budget. The fix is not more staff. It is a single list where every activation milestone has an owner, a date and a blocker field, reviewed weekly, with a status line the sponsor can read.
That is the study startup tracker and feasibility response generator described on the clinical research industry page: milestones in one place with reminders, and feasibility answers drafted from a maintained site profile for the site to review and sign. Neither is a system of record, and neither makes a regulatory decision. Once a study is enrolling, the same discipline applies to the first hour after a referral.
What happens next
FDA takes applications until October 30, selects the first cohort by December 18, and says the timeline may shift with volume. The pilot is small. Eight to ten pairs will not move national numbers on their own. What it signals is where FDA thinks early-phase time is lost, and a site that can show a documented, dated activation plan is the partner a selected sponsor will look for first.
